Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 1

What is the future of peer review? Why is there fraud in science? Is plagiarism out of control? Why do scientists do bad things? Is it all a case of: “All that is necessary for the triumph of evil is that good men do nothing?”

Authors Chris R Triggle, David J Triggle

Published 15 March 2007 Volume 2007:3(1) Pages 39—53

Chris R Triggle1, David J Triggle2

1School of Medical Sciences, RMIT University, Melbourne, Victoria, Australia; 2School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo NY, USA

Abstract: Peer review is an essential component of the process that is universally applied prior to the acceptance of a manuscript, grant or other scholarly work. Most of us willingly accept the responsibilities that come with being a reviewer but how comfortable are we with the process? Peer review is open to abuse but how should it be policed and can it be improved? A bad peer review process can inadvertently ruin an individual’s career, but are there penalties for policing a reviewer who deliberately sabotages a manuscript or grant? Science has received an increasingly tainted name because of recent high profile cases of alleged scientific misconduct. Once considered the results of work stress or a temporary mental health problem, scientific misconduct is increasingly being reported and proved to be a repeat offence. How should scientific misconduct be handled—is it a criminal offence and subject to national or international law? Similarly plagiarism is an ever-increasing concern whether at the level of the student or a university president. Are the existing laws tough enough? These issues, with appropriate examples, are dealt with in this review.

Keywords: peer review, journal impact factors, conflicts of interest, scientific misconduct, plagiarism

Download Article [PDF] 

Readers of this article also read:

Primary malignant lymphoma of the uterus and broad ligament: a case report and review of literature

Chen R, Yu Z, Zhang H, Ding J, Chen B

OncoTargets and Therapy 2015, 8:265-268

Published Date: 29 January 2015

Anemia associated with chronic heart failure: current concepts

Shah R, Agarwal AK

Clinical Interventions in Aging 2013, 8:111-122

Published Date: 4 February 2013

Treatment of pediatric pulmonary hypertension

Amy Hawkins, Robert Tulloh

Vascular Health and Risk Management 2009, 5:509-524

Published Date: 3 June 2009

Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers

Camelia R Ban, Stephen M Twigg

Vascular Health and Risk Management 2008, 4:575-596

Published Date: 6 June 2008

Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer’s disease

William J McGeown, Michael F Shanks, Annalena Venneri

Neuropsychiatric Disease and Treatment 2008, 4:465-476

Published Date: 11 April 2008

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Vascular Health and Risk Management 2007, 3:967-973

Published Date: 15 January 2008

Risk assessment for cancer surgery in elderly patients

Hodigere SJ Ramesh, Tom Boase, Riccardo A Audisio

Clinical Interventions in Aging 2006, 1:221-227

Published Date: 15 September 2006

Ximelagatran: direct thrombin inhibitor

Shir-Jing Ho, Tim A Brighton

Vascular Health and Risk Management 2006, 2:49-58

Published Date: 15 March 2006